Bio-Techne (TECH) Cash from Operations (2009 - 2026)
Bio-Techne (TECH) posted quarterly Cash from Operations of 86661000.0 for Q1 2026, up 110.75% year-over-year from 41120000.0 in Q1 2025, and up 5.16% quarter-over-quarter from 82411000.0 in Q4 2025.
Analysis
Bio-Techne (TECH) Cash from Operations (2009 - 2026) Analysis & Trends
Bio-Techne's Cash from Operations history runs 18 years deep, the most recent figure standing at 86661000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 110.75% year-over-year to 86661000.0; the TTM figure through Mar 2026 stood at 294858000.0 (up 11.33% YoY), while the FY2025 annual figure was 287556000.0, down 3.82% from the prior year.
- Cash from Operations for Q1 2026 stood at 86661000.0, up from 82411000.0 in the prior quarter.
- The five-year high for Cash from Operations was 102717000.0 in Q2 2022, with the low at 27585000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 75496000.0 (2024), against an average of 71378352.94.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations plunged 56.82% in 2025, then jumped 110.75% in 2026.
- Bio-Techne's Cash from Operations stood at 64384000.0 in 2022, then increased by 29.09% to 83116000.0 in 2023, then grew by 1.48% to 84346000.0 in 2024, then retreated by 2.29% to 82411000.0 in 2025, then rose by 5.16% to 86661000.0 in 2026.
- Business Quant data shows TECH's Cash from Operations at 86661000.0 in Q1 2026, 82411000.0 in Q4 2025, and 27585000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn | 95.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 95.42 Mn |
| Mar 31, 2026 | 86.66 Mn |
| Dec 31, 2025 | 82.41 Mn |
| Sep 30, 2025 | 27.59 Mn |
| Jun 30, 2025 | 98.20 Mn |
| Mar 31, 2025 | 41.12 Mn |
| Dec 31, 2024 | 84.35 Mn |
| Sep 30, 2024 | 63.89 Mn |
| Jun 30, 2024 | 75.50 Mn |
| Mar 31, 2024 | 80.99 Mn |
| Dec 31, 2023 | 83.12 Mn |
| Sep 30, 2023 | 59.38 Mn |
| Jun 30, 2023 | 83.39 Mn |
| Mar 31, 2023 | 50.54 Mn |
| Dec 31, 2022 | 64.38 Mn |
| Sep 30, 2022 | 56.08 Mn |
| Jun 30, 2022 | 102.72 Mn |
| Mar 31, 2022 | 73.13 Mn |
| Dec 31, 2021 | 100.99 Mn |
| Sep 30, 2021 | 48.43 Mn |